Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

NK Response Correlates with HIV Decrease in Pegylated IFN-α2a-Treated Antiretroviral Therapy-Suppressed Subjects.

Papasavvas E, Azzoni L, Kossenkov AV, Dawany N, Morales KH, Fair M, Ross BN, Lynn K, Mackiewicz A, Mounzer K, Tebas P, Jacobson JM, Kostman JR, Showe L, Montaner LJ.

J Immunol. 2019 Jun 28. pii: ji1801511. doi: 10.4049/jimmunol.1801511. [Epub ahead of print]

PMID:
31253727
2.

Placebo-controlled randomized clinical trial testing the efficacy and safety of varenicline for smokers with HIV.

Ashare RL, Thompson M, Serrano K, Leone F, Metzger D, Frank I, Gross R, Hole A, Mounzer K, Collman RG, Wileyto EP, Schnoll R.

Drug Alcohol Depend. 2019 Jul 1;200:26-33. doi: 10.1016/j.drugalcdep.2019.03.011. Epub 2019 May 7.

PMID:
31082665
3.

Differences in the rate of nicotine metabolism among smokers with and without HIV.

Ashare RL, Thompson M, Leone F, Metzger D, Gross R, Mounzer K, Tyndale RF, Lerman C, Mahoney MC, Cinciripini P, George TP, Collman RG, Schnoll R.

AIDS. 2019 May 1;33(6):1083-1088. doi: 10.1097/QAD.0000000000002127.

PMID:
30946162
4.

HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study.

Mounzer K, Hsu R, Fusco JS, Brunet L, Henegar CE, Vannappagari V, Stainsby CM, Shaefer MS, Ragone L, Fusco GP.

AIDS Res Ther. 2019 Jan 16;16(1):1. doi: 10.1186/s12981-019-0217-3.

5.

Psychiatric outcomes observed in patients living with HIV using six common core antiretrovirals in the Observational Pharmaco-Epidemiology Research and Analysis database.

Hsu R, Fusco J, Henegar C, Mounzer K, Wohlfeiler M, Vannappagari V, Aboud M, Curtis L, Fusco G.

Ther Adv Drug Saf. 2018 Oct 29;9(12):675-686. doi: 10.1177/2042098618798350. eCollection 2018 Dec.

6.

Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure.

Stainsby CM, Perger TM, Vannappagari V, Mounzer KC, Hsu RK, Henegar CE, Oyee J, Urbaityte R, Lane CE, Carter LM, Pakes GE, Shaefer MS.

Pharmacotherapy. 2019 Jan;39(1):40-54. doi: 10.1002/phar.2196. Epub 2018 Dec 11.

7.

Brief Report: Rate of Nicotine Metabolism and Tobacco Use Among Persons With HIV: Implications for Treatment and Research.

Schnoll RA, Thompson M, Serrano K, Leone F, Metzger D, Frank I, Gross R, Mounzer K, Tyndale RF, Weisbrot J, Meline M, Collman RG, Ashare RL.

J Acquir Immune Defic Syndr. 2019 Feb 1;80(2):e36-e40. doi: 10.1097/QAI.0000000000001895.

PMID:
30399039
8.

Analytical antiretroviral therapy interruption does not irreversibly change preinterruption levels of cellular HIV.

Papasavvas E, Lada SM, Joseph J, Yin X, Liu Q, Azzoni L, Mounzer K, Kostman JR, Richman D, Montaner LJ.

AIDS. 2018 Aug 24;32(13):1763-1772. doi: 10.1097/QAD.0000000000001909.

PMID:
30045057
9.

Delivery of TDF/FTC for Pre-exposure Prophylaxis to Prevent HIV-1 Acquisition in Young Adult Men Who Have Sex With Men and Transgender Women of Color Using a Urine Adherence Assay.

Lalley-Chareczko L, Clark D, Conyngham C, Zuppa A, Moorthy G, Mounzer K, Koenig H.

J Acquir Immune Defic Syndr. 2018 Oct 1;79(2):173-178. doi: 10.1097/QAI.0000000000001772.

PMID:
29905593
10.

CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells.

Abdel-Mohsen M, Kuri-Cervantes L, Grau-Exposito J, Spivak AM, Nell RA, Tomescu C, Vadrevu SK, Giron LB, Serra-Peinado C, Genescà M, Castellví J, Wu G, Del Rio Estrada PM, González-Navarro M, Lynn K, King CT, Vemula S, Cox K, Wan Y, Li Q, Mounzer K, Kostman J, Frank I, Paiardini M, Hazuda D, Reyes-Terán G, Richman D, Howell B, Tebas P, Martinez-Picado J, Planelles V, Buzon MJ, Betts MR, Montaner LJ.

Sci Transl Med. 2018 Apr 18;10(437). pii: eaar6759. doi: 10.1126/scitranslmed.aar6759.

11.

Frontline Science: Plasma and immunoglobulin G galactosylation associate with HIV persistence during antiretroviral therapy.

Vadrevu SK, Trbojevic-Akmacic I, Kossenkov AV, Colomb F, Giron LB, Anzurez A, Lynn K, Mounzer K, Landay AL, Kaplan RC, Papasavvas E, Montaner LJ, Lauc G, Abdel-Mohsen M.

J Leukoc Biol. 2018 Sep;104(3):461-471. doi: 10.1002/JLB.3HI1217-500R. Epub 2018 Apr 6.

PMID:
29633346
12.

Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.

Koenig HC, Mounzer K, Daughtridge GW, Sloan CE, Lalley-Chareczko L, Moorthy GS, Conyngham SC, Zuppa AF, Montaner LJ, Tebas P.

HIV Med. 2017 Jul;18(6):412-418. doi: 10.1111/hiv.12518. Epub 2017 Apr 26.

13.

The nature and consequences of cognitive deficits among tobacco smokers with HIV: a comparison to tobacco smokers without HIV.

Harrison JD, Dochney JA, Blazekovic S, Leone F, Metzger D, Frank I, Gross R, Hole A, Mounzer K, Siegel S, Schnoll RA, Ashare RL.

J Neurovirol. 2017 Aug;23(4):550-557. doi: 10.1007/s13365-017-0526-z. Epub 2017 Apr 20.

14.

HCV viraemia associates with NK cell activation and dysfunction in antiretroviral therapy-treated HIV/HCV-co-infected subjects.

Papasavvas E, Azzoni L, Yin X, Liu Q, Joseph J, Mackiewicz A, Ross B, Lynn KM, Jacobson JM, Mounzer K, Kostman JR, Montaner LJ.

J Viral Hepat. 2017 Oct;24(10):865-876. doi: 10.1111/jvh.12714. Epub 2017 May 11.

15.

A case study of chewed Truvada® for PrEP maintaining protective drug levels as measured by a novel urine tenofovir assay.

Lalley-Chareczko L, Clark D, Zuppa AF, Moorthy G, Conyngham C, Mounzer K, Koenig H.

Antivir Ther. 2017;22(7):639-641. doi: 10.3851/IMP3151. Epub 2017 Mar 6.

PMID:
28260694
16.

The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial.

Dinges W, Girard PM, Podzamczer D, Brockmeyer NH, García F, Harrer T, Lelievre JD, Frank I, Colin De Verdière N, Yeni GP, Ortega Gonzalez E, Rubio R, Clotet Sala B, DeJesus E, Pérez-Elias MJ, Launay O, Pialoux G, Slim J, Weiss L, Bouchaud O, Felizarta F, Meurer A, Raffi F, Esser S, Katlama C, Koletar SL, Mounzer K, Swindells S, Baxter JD, Schneider S, Chas J, Molina JM, Koutsoukos M, Collard A, Bourguignon P, Roman F.

Medicine (Baltimore). 2016 Feb;95(6):e2673. doi: 10.1097/MD.0000000000002673.

17.

Barriers and facilitators to patient retention in HIV care.

Yehia BR, Stewart L, Momplaisir F, Mody A, Holtzman CW, Jacobs LM, Hines J, Mounzer K, Glanz K, Metlay JP, Shea JA.

BMC Infect Dis. 2015 Jun 28;15:246. doi: 10.1186/s12879-015-0990-0.

18.

Impact of the Outpatient Clinic Experience on Retention in Care: Perspectives of HIV-Infected Patients and Their Providers.

Yehia BR, Mody A, Stewart L, Holtzman CW, Jacobs LM, Hines J, Mounzer K, Glanz K, Metlay JP, Shea JA.

AIDS Patient Care STDS. 2015 Jul;29(7):365-9. doi: 10.1089/apc.2015.0049. Epub 2015 Jun 10. No abstract available.

PMID:
26061902
19.

Correction for Patro et al., Shift in Monocyte Apoptosis with Increasing Viral Load and Change in Apoptosis-Related ISG/Bcl2 Family Gene Expression in Chronically HIV-1-Infected Subjects.

Patro SC, Pal S, Bi Y, Lynn K, Mounzer KC, Kostman JR, Davuluri RV, Montaner LJ.

J Virol. 2015 Jul;89(13):6970. doi: 10.1128/JVI.00735-15. No abstract available.

20.

Structural Bone Deficits in HIV/HCV-Coinfected, HCV-Monoinfected, and HIV-Monoinfected Women.

Lo Re V 3rd, Lynn K, Stumm ER, Long J, Nezamzadeh MS, Baker JF, Hoofnagle AN, Kapalko AJ, Mounzer K, Zemel BS, Tebas P, Kostman JR, Leonard MB.

J Infect Dis. 2015 Sep 15;212(6):924-33. doi: 10.1093/infdis/jiv147. Epub 2015 Mar 9.

21.

Plasmacytoid dendritic cell and functional HIV Gag p55-specific T cells before treatment interruption can inform set-point plasma HIV viral load after treatment interruption in chronically suppressed HIV-1(+) patients.

Papasavvas E, Foulkes A, Yin X, Joseph J, Ross B, Azzoni L, Kostman JR, Mounzer K, Shull J, Montaner LJ.

Immunology. 2015 Jul;145(3):380-90. doi: 10.1111/imm.12452. Epub 2015 May 19.

22.

Mapping patient-identified barriers and facilitators to retention in HIV care and antiretroviral therapy adherence to Andersen's Behavioral Model.

Holtzman CW, Shea JA, Glanz K, Jacobs LM, Gross R, Hines J, Mounzer K, Samuel R, Metlay JP, Yehia BR.

AIDS Care. 2015;27(7):817-28. doi: 10.1080/09540121.2015.1009362. Epub 2015 Feb 11. Review.

23.

Shift in monocyte apoptosis with increasing viral load and change in apoptosis-related ISG/Bcl2 family gene expression in chronically HIV-1-infected subjects.

Patro SC, Pal S, Bi Y, Lynn K, Mounzer KC, Kostman JR, Davuluri RV, Montaner LJ.

J Virol. 2015 Jan;89(1):799-810. doi: 10.1128/JVI.02382-14. Epub 2014 Oct 29. Erratum in: J Virol. 2015 Jul;89(13):6970.

24.

A correlate of HIV-1 control consisting of both innate and adaptive immune parameters best predicts viral load by multivariable analysis in HIV-1 infected viremic controllers and chronically-infected non-controllers.

Tomescu C, Liu Q, Ross BN, Yin X, Lynn K, Mounzer KC, Kostman JR, Montaner LJ.

PLoS One. 2014 Jul 31;9(7):e103209. doi: 10.1371/journal.pone.0103209. eCollection 2014.

25.

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.

Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, Luetkemeyer AF, Asmuth D, Gaggar A, Ni L, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Rodriguez-Torres M, Dieterich D; PHOTON-1 Investigators.

JAMA. 2014 Jul 23-30;312(4):353-61. doi: 10.1001/jama.2014.7734. Erratum in: JAMA. 2014 Nov 12;312(18):1932.

26.

Isolated hepatitis B surface antigenemia in an HIV-1-positive individual.

Smith S, Mounzer K.

AIDS. 2014 Jun 1;28(9):1375-6. doi: 10.1097/QAD.0000000000000226. No abstract available.

PMID:
24959966
27.

Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy.

Hafkin JS, Osborn MK, Localio AR, Amorosa VK, Kostman JR, Stern JJ, De La Torre P, Mounzer K, Frank I, Gross R, Chang KM, Lo Re V 3rd.

J Viral Hepat. 2014 Apr;21(4):288-96. doi: 10.1111/jvh.12142. Epub 2013 Jul 30.

28.

Preventive cancer screening practices in HIV-positive patients.

Momplaisir F, Mounzer K, Long JA.

AIDS Care. 2014 Jan;26(1):87-94. doi: 10.1080/09540121.2013.802276. Epub 2013 Jun 6.

PMID:
23742681
29.

Vaccinating HIV patients: focus on human papillomavirus and herpes zoster vaccines.

Koenig HC, Garland JM, Weissman D, Mounzer K.

AIDS Rev. 2013 Apr-Jun;15(2):77-86. Review.

PMID:
23681435
30.

Seminal human immunodeficiency virus blips and structured natural conception in serodiscordant couples.

Mounzer KC, DiNubile MJ.

J Infect Dis. 2013 Aug 15;208(4):710-1. doi: 10.1093/infdis/jit219. Epub 2013 May 10. No abstract available.

PMID:
23667137
31.

Improved treatment for primary HIV infection by interferon-alfa therapy? Does HCV treatment in HIV/HCV coinfected patients help us to test this hypothesis? Reply to zur Wiesch and van Lunzen.

Azzoni L, Foulkes AS, Papasavvas E, Mexas AM, Lynn KM, Mounzer K, Tebas P, Jacobson JM, Frank I, O'Doherty U, Kostman J, Montaner LJ.

J Infect Dis. 2013 Jul 15;208(2):363. doi: 10.1093/infdis/jit160. Epub 2013 Apr 9. No abstract available.

PMID:
23570845
32.

Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study.

Squires KE, Bekker LG, Eron JJ, Cheng B, Rockstroh JK, Marquez F, Kumar P, Thompson M, Campo RE, Mounzer K, Strohmaier KM, Lu C, Rodgers A, Jackson BE, Wenning LA, Robertson M, Nguyen BY, Sklar P; REALMRK Investigators.

AIDS Res Hum Retroviruses. 2013 Jun;29(6):859-70. doi: 10.1089/AID.2012.0292. Epub 2013 Feb 26.

33.

Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration.

Azzoni L, Foulkes AS, Papasavvas E, Mexas AM, Lynn KM, Mounzer K, Tebas P, Jacobson JM, Frank I, Busch MP, Deeks SG, Carrington M, O'Doherty U, Kostman J, Montaner LJ.

J Infect Dis. 2013 Jan 15;207(2):213-22. doi: 10.1093/infdis/jis663. Epub 2012 Oct 26.

34.

Constitutive gene expression in monocytes from chronic HIV-1 infection overlaps with acute Toll-like receptor induced monocyte activation profiles.

Gekonge B, Giri MS, Kossenkov AV, Nebozyhn M, Yousef M, Mounzer K, Showe L, Montaner LJ.

PLoS One. 2012;7(7):e41153. doi: 10.1371/journal.pone.0041153. Epub 2012 Jul 18.

35.

Retinoblastoma protein induction by HIV viremia or CCR5 in monocytes exposed to HIV-1 mediates protection from activation-induced apoptosis: ex vivo and in vitro study.

Gekonge B, Raymond AD, Yin X, Kostman J, Mounzer K, Collman RG, Showe L, Montaner LJ.

J Leukoc Biol. 2012 Aug;92(2):397-405. doi: 10.1189/jlb.1111552. Epub 2012 Jun 13.

36.

Prioritizing CD4 count monitoring in response to ART in resource-constrained settings: a retrospective application of prediction-based classification.

Azzoni L, Foulkes AS, Liu Y, Li X, Johnson M, Smith C, Kamarulzaman AB, Montaner J, Mounzer K, Saag M, Cahn P, Cesar C, Krolewiecki A, Sanne I, Montaner LJ.

PLoS Med. 2012;9(4):e1001207. doi: 10.1371/journal.pmed.1001207. Epub 2012 Apr 17.

37.

Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.

Skiest DJ, Cohen C, Mounzer K, Haigney Z, Barker D, Gottlieb M, Bellman PC, Dejesus E, Khanlou H, Ruane PJ, Hsiao CB, Abriola K, Rashbaum B, Bellos N, Ward D, Colson A, Santiago F, Habel A, Garb J.

HIV Clin Trials. 2011 May-Jun;12(3):131-40. doi: 10.1310/hct1203-131.

PMID:
21684853
38.

Prediction based classification for longitudinal biomarkers.

Foulkes AS, Azzoni L, Li X, Johnson MA, Smith C, Mounzer K, Montaner LJ.

Ann Appl Stat. 2010 Sep;4(3):1476-1497.

39.

Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid.

Lee SR, Kardos KW, Schiff E, Berne CA, Mounzer K, Banks AT, Tatum HA, Friel TJ, Demicco MP, Lee WM, Eder SE, Monto A, Yearwood GD, Guillon GB, Kurtz LA, Fischl M, Unangst JL, Kriebel L, Feiss G, Roehler M.

J Virol Methods. 2011 Mar;172(1-2):27-31. doi: 10.1016/j.jviromet.2010.12.009. Epub 2010 Dec 21.

PMID:
21182871
40.

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.

International HIV Controllers Study, Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D, Graham RR, Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J, Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw A, Burtt NP, Guiducci C, Gupta N, Gao X, Qi Y, Yuki Y, Piechocka-Trocha A, Cutrell E, Rosenberg R, Moss KL, Lemay P, O'Leary J, Schaefer T, Verma P, Toth I, Block B, Baker B, Rothchild A, Lian J, Proudfoot J, Alvino DM, Vine S, Addo MM, Allen TM, Altfeld M, Henn MR, Le Gall S, Streeck H, Haas DW, Kuritzkes DR, Robbins GK, Shafer RW, Gulick RM, Shikuma CM, Haubrich R, Riddler S, Sax PE, Daar ES, Ribaudo HJ, Agan B, Agarwal S, Ahern RL, Allen BL, Altidor S, Altschuler EL, Ambardar S, Anastos K, Anderson B, Anderson V, Andrady U, Antoniskis D, Bangsberg D, Barbaro D, Barrie W, Bartczak J, Barton S, Basden P, Basgoz N, Bazner S, Bellos NC, Benson AM, Berger J, Bernard NF, Bernard AM, Birch C, Bodner SJ, Bolan RK, Boudreaux ET, Bradley M, Braun JF, Brndjar JE, Brown SJ, Brown K, Brown ST, Burack J, Bush LM, Cafaro V, Campbell O, Campbell J, Carlson RH, Carmichael JK, Casey KK, Cavacuiti C, Celestin G, Chambers ST, Chez N, Chirch LM, Cimoch PJ, Cohen D, Cohn LE, Conway B, Cooper DA, Cornelson B, Cox DT, Cristofano MV, Cuchural G Jr, Czartoski JL, Dahman JM, Daly JS, Davis BT, Davis K, Davod SM, DeJesus E, Dietz CA, Dunham E, Dunn ME, Ellerin TB, Eron JJ, Fangman JJ, Farel CE, Ferlazzo H, Fidler S, Fleenor-Ford A, Frankel R, Freedberg KA, French NK, Fuchs JD, Fuller JD, Gaberman J, Gallant JE, Gandhi RT, Garcia E, Garmon D, Gathe JC Jr, Gaultier CR, Gebre W, Gilman FD, Gilson I, Goepfert PA, Gottlieb MS, Goulston C, Groger RK, Gurley TD, Haber S, Hardwicke R, Hardy WD, Harrigan PR, Hawkins TN, Heath S, Hecht FM, Henry WK, Hladek M, Hoffman RP, Horton JM, Hsu RK, Huhn GD, Hunt P, Hupert MJ, Illeman ML, Jaeger H, Jellinger RM, John M, Johnson JA, Johnson KL, Johnson H, Johnson K, Joly J, Jordan WC, Kauffman CA, Khanlou H, Killian RK, Kim AY, Kim DD, Kinder CA, Kirchner JT, Kogelman L, Kojic EM, Korthuis PT, Kurisu W, Kwon DS, LaMar M, Lampiris H, Lanzafame M, Lederman MM, Lee DM, Lee JM, Lee MJ, Lee ET, Lemoine J, Levy JA, Llibre JM, Liguori MA, Little SJ, Liu AY, Lopez AJ, Loutfy MR, Loy D, Mohammed DY, Man A, Mansour MK, Marconi VC, Markowitz M, Marques R, Martin JN, Martin HL Jr, Mayer KH, McElrath MJ, McGhee TA, McGovern BH, McGowan K, McIntyre D, Mcleod GX, Menezes P, Mesa G, Metroka CE, Meyer-Olson D, Miller AO, Montgomery K, Mounzer KC, Nagami EH, Nagin I, Nahass RG, Nelson MO, Nielsen C, Norene DL, O'Connor DH, Ojikutu BO, Okulicz J, Oladehin OO, Oldfield EC 3rd, Olender SA, Ostrowski M, Owen WF Jr, Pae E, Parsonnet J, Pavlatos AM, Perlmutter AM, Pierce MN, Pincus JM, Pisani L, Price LJ, Proia L, Prokesch RC, Pujet HC, Ramgopal M, Rathod A, Rausch M, Ravishankar J, Rhame FS, Richards CS, Richman DD, Rodes B, Rodriguez M, Rose RC 3rd, Rosenberg ES, Rosenthal D, Ross PE, Rubin DS, Rumbaugh E, Saenz L, Salvaggio MR, Sanchez WC, Sanjana VM, Santiago S, Schmidt W, Schuitemaker H, Sestak PM, Shalit P, Shay W, Shirvani VN, Silebi VI, Sizemore JM Jr, Skolnik PR, Sokol-Anderson M, Sosman JM, Stabile P, Stapleton JT, Starrett S, Stein F, Stellbrink HJ, Sterman FL, Stone VE, Stone DR, Tambussi G, Taplitz RA, Tedaldi EM, Telenti A, Theisen W, Torres R, Tosiello L, Tremblay C, Tribble MA, Trinh PD, Tsao A, Ueda P, Vaccaro A, Valadas E, Vanig TJ, Vecino I, Vega VM, Veikley W, Wade BH, Walworth C, Wanidworanun C, Ward DJ, Warner DA, Weber RD, Webster D, Weis S, Wheeler DA, White DJ, Wilkins E, Winston A, Wlodaver CG, van't Wout A, Wright DP, Yang OO, Yurdin DL, Zabukovic BW, Zachary KC, Zeeman B, Zhao M.

Science. 2010 Dec 10;330(6010):1551-7. doi: 10.1126/science.1195271. Epub 2010 Nov 4.

41.

Retention of functional DC-NK cross-talk following up to 18 weeks therapy interruptions in chronically suppressed HIV type 1+ subjects.

Papasavvas E, Chehimi J, Azzoni L, Pistilli M, Thiel B, Mackiewicz A, Creer S, Mounzer K, Kostman JR, Montaner LJ.

AIDS Res Hum Retroviruses. 2010 Oct;26(10):1047-9. doi: 10.1089/aid.2010.0020. Epub 2010 Aug 18. No abstract available.

42.

Increased plasmacytoid dendritic cell maturation and natural killer cell activation in HIV-1 exposed, uninfected intravenous drug users.

Tomescu C, Duh FM, Lanier MA, Kapalko A, Mounzer KC, Martin MP, Carrington M, Metzger DS, Montaner LJ.

AIDS. 2010 Sep 10;24(14):2151-60. doi: 10.1097/QAD.0b013e32833dfc20.

43.

Increased metallothionein gene expression, zinc, and zinc-dependent resistance to apoptosis in circulating monocytes during HIV viremia.

Raymond AD, Gekonge B, Giri MS, Hancock A, Papasavvas E, Chehimi J, Kossenkov AV, Nicols C, Yousef M, Mounzer K, Shull J, Kostman J, Showe L, Montaner LJ.

J Leukoc Biol. 2010 Sep;88(3):589-96. doi: 10.1189/jlb.0110051. Epub 2010 Jun 15. Erratum in: J Leukoc Biol. 2010 Nov;88(5):1061. Kossevkov, Andrew V [corrected to Kossenkov, Andrew V]. J Leukoc Biol. 2010 Nov;88(5):1061a.

44.

The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients.

Amorosa VK, Slim J, Mounzer K, Bruno C, Hoffman-Terry M, Dorey-Stein Z, Ferrara T, Kostman JR, Lo Re V 3rd.

Antivir Ther. 2010;15(1):91-9. doi: 10.3851/IMP1492.

45.

Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.

Hodder SL, Mounzer K, Dejesus E, Ebrahimi R, Grimm K, Esker S, Ecker J, Farajallah A, Flaherty JF; AI266073 Study Group.

AIDS Patient Care STDS. 2010 Feb;24(2):87-96. doi: 10.1089/apc.2009.0259.

PMID:
20156091
46.

Inability of plasmacytoid dendritic cells to directly lyse HIV-infected autologous CD4+ T cells despite induction of tumor necrosis factor-related apoptosis-inducing ligand.

Chehimi J, Papasavvas E, Tomescu C, Gekonge B, Abdulhaqq S, Raymond A, Hancock A, Vinekar K, Carty C, Reynolds G, Pistilli M, Mounzer K, Kostman J, Montaner LJ.

J Virol. 2010 Mar;84(6):2762-73. doi: 10.1128/JVI.01350-09. Epub 2009 Dec 30.

47.

Circulating monocytes in HIV-1-infected viremic subjects exhibit an antiapoptosis gene signature and virus- and host-mediated apoptosis resistance.

Giri MS, Nebozyhn M, Raymond A, Gekonge B, Hancock A, Creer S, Nicols C, Yousef M, Foulkes AS, Mounzer K, Shull J, Silvestri G, Kostman J, Collman RG, Showe L, Montaner LJ.

J Immunol. 2009 Apr 1;182(7):4459-70. doi: 10.4049/jimmunol.0801450.

48.

Evidence of a decrease in CD4 recovery once back on antiretroviral therapy after sequential > or =6 weeks antiretroviral therapy interruptions.

Papasavvas E, Foulkes A, Li X, Kostman JR, Mounzer KC, Montaner LJ.

J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):334-5. doi: 10.1097/QAI.0b013e3181966b0c. No abstract available.

49.

Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients.

Papasavvas E, Pistilli M, Reynolds G, Bucki R, Azzoni L, Chehimi J, Janmey PA, DiNubile MJ, Ondercin J, Kostman JR, Mounzer KC, Montaner LJ.

AIDS. 2009 Jan 28;23(3):369-75. doi: 10.1097/QAD.0b013e32831e9c76.

50.

Antiretroviral therapy in HIV-infected patients with multidrug-resistant virus: applying the guidelines to practice.

Kaplan SS, Mounzer KC.

AIDS Patient Care STDS. 2008 Dec;22(12):931-40. doi: 10.1089/apc.2008.0021.

PMID:
19072099

Supplemental Content

Loading ...
Support Center